In-vitro characterization of the cytochrome P450 isoenzymes involved in the back oxidation and N-dealkylation of reduced haloperidol

Pharmacogenetics

Volumn 8, Issue 5, 1998, Pages 383-389

  Pan, L P ^a   De Vriendt, C ^a   Belpaire, E M ^a  

^a GHENT UNIVERSITY   (Belgium)

Author keywords

CYP2D6; CYP3A4; Cytochrome P450 isoenzymes; Haloperidol; Human liver microsomes; Reduced haloperidol

Indexed keywords

4 (4 CHLOROPHENYL) 4 HYDROXYPIPERIDINE; CYTOCHROME P450; CYTOCHROME P450 ISOENZYME; DEBRISOQUINE 4 HYDROXYLASE; DRUG METABOLITE; FURAFYLLINE; HALOPERIDOL; KETOCONAZOLE; PAROXETINE; QUINIDINE; REDUCED HALOPERIDOL; TROLEANDOMYCIN; UNCLASSIFIED DRUG;

ARTICLE; BLOOD LEVEL; CORRELATION FUNCTION; DEALKYLATION; DRUG INHIBITION; DRUG METABOLISM; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME KINETICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LIVER MICROSOME; PRIORITY JOURNAL; REACTION ANALYSIS;

ADOLESCENT; ADULT; AGED; CHILD; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DEALKYLATION; HALOPERIDOL; HUMANS; ISOENZYMES; MICROSOMES, LIVER; MIDDLE AGED; MIXED FUNCTION OXYGENASES; OXIDATION-REDUCTION; PIPERIDINES;

EID: 0031712064     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199810000-00003     Document Type: Article

References (24)

1. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein using the principle of protein-dye binding. Anal Biochem 1976; 72:248-252.
2. Dixon M. The determination of enzyme inhibitor constants. Biochem J 1953; 55:170-171.
3. Fang J, Baker GB, Silverstone PH, Coutts RT. Involvement of CYP3A4 and CYP2D6 in the metabolism of halopericlol. Cell Molec Neurobiol 1997; 17:227-233.
4. Gorrod JW, Fang J. On the metabolism of haloperidol. Xenobiotica 1993: 23:495-508.
5. Gorski JC, Jones DR, Wrighton SA, Hall SD. Characterization of dextromethorphan N-demethylation by human liver microsomes. Contribution of the cytochrome P4503A4 (CYP3A4) subfamily. Biochem Pharmacol 1994; 48:173-182.
6. Gram LF, Debruyne D, Caillard V, Boulenger JP, Lacotte J, Moulin M, Xarifian E. Substantial rise in sparteine metabolic ratio during haloperidol treatment. Br J Clin Pharmacol 1989; 27:272-275.
7. Inaba T, Jurima M, Mahon WA, Kaloww W. In vitro inhibition of two isoenzymes of human liver cytochrome P-450: mephenytoin p-hydroxylase and sparteine monooxygenase. Drug Metab Dispos 1985; 13:443-448.
8. Jacqz-Aigrain E, Funck-Brentano C, Cresteil T. CYP2D6- and CYP3A4-dependent metabolism of dextromethorphan in humans. Pharmacogenetics 1993; 3:197-204.
9. Korpi ER, Costalos DT, Wyatt RJ. Interconversions of haloperidol and reduced haloperidol in guinea pig and rat liver microsomes. Biochem Pharmacol 1985; 34:2923-2927.
10. Lane H, Hu YPO, Jann MW, Deng H, Lin H, Chang W. Dextromethorphan phenotyping and haloperidol disposition in schizophrenic patients. Psychiatry Res 1997; 69:105-111.
11. LLerena A, Alm C, Dahl M, Ekqvist B, Bertilsson L. Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype. Ther Drug Monit 1992a: 14:92-97.
12. LLerena A, Dahl M, Ekqvist B, Bertilsson L. Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers. Ther Drug Monit 1992b; 14:261-264.
13. Midha KK, Hales EM, Hubbard JW, Korchinski ED, McKay G. Interconversion between haloperidol and reduced haloperidol in humans. J Clin Psychopharmacol 1987; 7:362-364.
14. Newton D, Wang RW, Lu AYH. Cytochrome P450 inhibitors: evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 1995: 23:154-158.
15. Oida T, Terauchi Y, Yoshida K, Kagemoto A, Sekine Y. Use of antisera in the isolation of human specific conjugates of haloperidol. Xenobiotica 1989; 19:781-793.
16. Pan LP, Wijnant P, De Vriendt C, Rosseel MT, Belpaire FM. Characterization of the cytochrome P450 isoenzymes involved in the in vitro N-dealkylation of haloperidol. Br J Clin Pharmacol 1997; 44:557-564.
17. Sesardic D, Boobis AR, Edwards RJ, Davies DS. A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking. Br J Clin Pharmacol 1988: 26:363-372.
18. Shou M, Grogan J, Mancewicz JA, Krausz KW, Gonzalez FJ, Gelboin HV, Korzekwa KR. Activiation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry 1994; 33:6450-6455.
19. Someya T, Inaba T, Tyndale R, Tang S, Takahashi S. Conversion of bromperidol to reduced bromperidol in human liver. Neuropsychopharmacology 1991; 5:177-182.
20. Suzuki A, Otani K, Mihara K, Yasui N, Kaneko S, Inoue Y, Hayashi K. Effects of the CYP2D6 genotype on the steady state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients. Pharmacogenetics 1997; 7:415-418.
21. Tsang MW, Shader RI, Greenblatt DJ. Metabolism of haloperidol: Clinical implications and unanswered questions. J Clin Psychopharmacol 1994; 14:159-162.
22. Tyndale RF, Kalow W, Inaba T. Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/ debrisoquine monooxygenase). Br J Clin Pharmacol 1991; 31:655-660.
23. Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 1992; 22:1-21.
24. Young D, Midha KK, Fossler MJ, Hawes EM, Hubbard JW, McKay G, Korchinski ED. Effect of quinidine on the interconversion kinetics between haloperidol and reduced haloperidol in humans: implications for the involvement of cytochrome P450IID6. Eur J Clin Pharmacol 1993; 44:433-438.